Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Nuvation Bio Inc. | Director | Class A Common Stock | 17.1M | $50.7M | $2.97 | Sep 4, 2024 | By Decheng Anbio Limited |
Nuvation Bio Inc. | Director | Class A Common Stock | 7.61M | $22.6M | $2.97 | Sep 4, 2024 | By Decheng Capital Global Healthcare Fund (Master), LP |
Nuvation Bio Inc. | Director | Class A Common Stock | 1.28M | $3.81M | $2.97 | Sep 4, 2024 | By Decheng Capital China Life Sciences USD Fund III, L.P. |
Cue Health Inc. | Director | Common Stock | 788K | $237K | $0.30 | Sep 28, 2021 | Indirect |
ALPINE IMMUNE SCIENCES, INC. | Director, 10%+ Owner | Common Stock | 0 | $0 | $6.33 | May 18, 2024 | Indirect |
Nuvation Bio Inc. | Director | Warrants (Right to Buy) | 438K | Sep 3, 2024 | By Decheng Anbio Limited | ||
Nuvation Bio Inc. | Director | Warrants (Right to Buy) | 175K | Sep 3, 2024 | By Decheng Capital Global Healthcare Fund (Master), LP | ||
Nuvation Bio Inc. | Director | Warrants (Right to Buy) | 32.9K | Sep 3, 2024 | By Decheng Capital China Life Sciences USD Fund III, L.P. | ||
ALPINE IMMUNE SCIENCES, INC. | Director, 10%+ Owner | Stock Option (Right to buy) | 0 | May 20, 2024 | Direct | ||
ALPINE IMMUNE SCIENCES, INC. | Director, 10%+ Owner | Warrant (right to buy) | 0 | Jan 18, 2024 | Indirect | ||
Cue Health Inc. | Director | Series C-1 Preferred Stock | 0 | Sep 28, 2021 | Indirect | ||
Nuvation Bio Inc. | Director | Series A Preferred Stock | 0 | Sep 4, 2024 | By Decheng Anbio Limited | ||
Nuvation Bio Inc. | Director | Series A Preferred Stock | 0 | Sep 4, 2024 | By Decheng Capital China Life Sciences USD Fund III, L.P. | ||
Nuvation Bio Inc. | Director | Series A Preferred Stock | 0 | Sep 4, 2024 | By Decheng Capital Global Healthcare Fund (Master), LP |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
NUVB | Nuvation Bio Inc. | Sep 3, 2024 | 12 | $0 | 4 | Sep 5, 2024 | Director |
NUVB | Nuvation Bio Inc. | Jun 25, 2024 | 1 | $825K | 4 | Jun 26, 2024 | Director |
NUVB | Nuvation Bio Inc. | Jun 20, 2024 | 3 | $1.49M | 4 | Jun 25, 2024 | Director |
ALPN | ALPINE IMMUNE SCIENCES, INC. | May 18, 2024 | 8 | $0 | 4 | May 20, 2024 | Director, 10%+ Owner |
NUVB | Nuvation Bio Inc. | Apr 9, 2024 | 3 | $0 | 4 | Apr 11, 2024 | Director |
NUVB | Nuvation Bio Inc. | Apr 9, 2024 | 0 | $0 | 3 | Apr 11, 2024 | Director |
ALPN | ALPINE IMMUNE SCIENCES, INC. | Jan 18, 2024 | 2 | $15.7M | 4 | Jan 22, 2024 | Director, 10%+ Owner |
ALPN | ALPINE IMMUNE SCIENCES, INC. | Jan 2, 2024 | 1 | $0 | 4 | Jan 4, 2024 | Director, 10%+ Owner |
ALPN | ALPINE IMMUNE SCIENCES, INC. | Nov 9, 2023 | 1 | $4.69M | 4 | Nov 14, 2023 | Director, 10%+ Owner |
ALPN | ALPINE IMMUNE SCIENCES, INC. | Jan 3, 2023 | 1 | $0 | 4 | Jan 5, 2023 | Director, 10%+ Owner |
ALPN | ALPINE IMMUNE SCIENCES, INC. | Sep 23, 2022 | 2 | $14.7M | 4 | Sep 27, 2022 | Director, 10%+ Owner |
ALPN | ALPINE IMMUNE SCIENCES, INC. | Jan 3, 2022 | 1 | $0 | 4 | Jan 4, 2022 | Director, 10%+ Owner |
HLTH | Cue Health Inc. | Sep 28, 2021 | 3 | $10.1M | 4 | Sep 30, 2021 | Director |
HLTH | Cue Health Inc. | Sep 23, 2021 | 0 | $0 | 3 | Sep 23, 2021 | Director, 10%+ Owner |
ALPN | ALPINE IMMUNE SCIENCES, INC. | Sep 17, 2021 | 1 | $14.5M | 4 | Sep 21, 2021 | Director, 10%+ Owner |